Intellia Therapeutics, Inc. 8-K

What Happened

• On February 26, 2026, Intellia Therapeutics, Inc. (NTLA) announced its financial results and business updates for the quarter and year ended December 31, 2025. The company furnished the full press release as Exhibit 99.1 to this Form 8-K. The filing was signed by CEO John M. Leonard.

Key Details

• Filing date: February 26, 2026; reporting period: quarter and year ended December 31, 2025.
• Exhibit filed: 99.1 — press release with the announced results and business updates; also included Interactive XBRL cover page (Exhibit 104).
• Reported under Item 2.02 (Results of Operations and Financial Condition); no executive changes or other reportable events disclosed in this filing.

Why It Matters

• This 8-K formally notifies investors that Intellia released its quarterly and full-year financial results and business progress; those results (revenue, net income/loss, cash position, and any guidance or program updates) will be in the furnished press release.
• Investors should review the Exhibit 99.1 press release for the specific financial figures and any commentary on commercial progress, clinical programs, or guidance, since those details can affect valuation and near-term trading. Keywords: earnings, quarterly results, financial results, CEO, press release.